#United States #New York #Class Action #Levi & Korsinsky #Skye Bioscience

Skye Bioscience Class Action Lawsuit Alert

Levi & Korsinsky, LLP has issued an important reminder to investors in Skye Bioscience, Inc. (NASDAQ: SKYE) regarding a pending class action lawsuit. Investors who have experienced losses due to alleged securities fraud should be aware that the deadline to appoint a lead plaintiff is January 16, 2026.

Overview of the Lawsuit

This class action seeks to recover losses sustained by Skye Bioscience investors between November 4, 2024, and October 3, 2025. The complaint presents serious allegations of misconduct, claiming that the company’s lead product, nimacimab, did not live up to the performance expectations set by the company, misleading investors. Specifically, it is alleged that:
1. The effectiveness of nimacimab was overstated.
2. The claimed clinical, regulatory, and commercial prospects of nimacimab were inflated.
3. Public statements made by the defendants were materially false and misleading.

These points underscore the serious nature of the allegations and the potential impact on investors who relied on the accuracy of the information provided by Skye Bioscience.

Next Steps for Affected Investors

For those who believe they've suffered losses during the specified timeframe, acting quickly is crucial. Interested parties have until January 16, 2026, to request the court to appoint them as lead plaintiffs. It's important to note that participation in the lawsuit does not necessitate serving as a lead plaintiff; potential class members can still seek compensation.

Levi & Korsinsky assures investors that, should they qualify as class members, they could obtain compensation without any out-of-pocket expenses or fees, emphasizing that there are no associated costs to join the class action.

The Expertise Behind Levi & Korsinsky

With a robust history spanning over two decades, Levi & Korsinsky has established itself as a formidable player in the realm of securities litigation. The firm has successfully secured hundreds of millions of dollars for disgruntled shareholders through its extensive experience and strategic approach to complex legal cases. Their notable performance has earned them a place in the ISS Securities Class Action Services' Top 50 Report consistently over the years.

Contact Information

For more personalized assistance, affected investors can reach out to Joseph E. Levi, Esq. directly via email at [email protected] or by calling (212) 363-7500. Potential plaintiffs are encouraged to follow the provided link for further information and assistance in the claim process.

In summary, this situation serves as a pressing reminder of the importance of investor vigilance and the potential for recourse through class action lawsuits in the face of alleged corporate misconduct. For Skye Bioscience investors, their opportunity to seek justice is approaching rapidly, making immediate action essential.